An observational study in Lung Cancer (Diagnosis), sponsored by Intuitive Surgical. Not yet recruiting at 4 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Intuitive Surgical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Lung Neoplasms by Intuitive Surgical — 4 open to participants now, 7 under way, none of them phase 3. Lung Neoplasms · Intuitive Surgical.
Among the 14 studies in Lung Neoplasms by Intuitive Surgical, this one is the only one that started in 2027, is one of 9 observational ones, and was the 14th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →4 of the 14 studies in Lung Neoplasms by Intuitive Surgical are open now, in 8 countries. Recruiting first, the newest first:
Intuitive Surgical · Sites in Germany, Switzerland, United Kingdom
Ages 18+
Intuitive Surgical · Sites in France, Germany, Switzerland and 1 more country
Ages 18+
Intuitive Surgical · Sites in Denmark, France, Germany and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 151 is below the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 354 across the 5 interventional studies, 288 across the 9 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Intuitive Surgical is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
1 of the studies in Lung Neoplasms by Intuitive Surgical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06004440Intuitive SurgicalReal World Registry for Use of the Ion Endoluminal System | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Lung Neoplasms by Intuitive Surgical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the diagnostic performance and safety of robotic-assisted bronchoscopy using the Ion Endoluminal System in adults with small lung nodules that do not show a bronchus sign on CT imaging.
The main questions it aims to answer are:
Participants who are already scheduled to undergo lung nodule biopsy using the Ion Endoluminal System and integrated mobile cone-beam CT (mCBCT) as part of their routine clinical care will be enrolled in this study.
Lung cancer remains a leading cause of cancer-related mortality worldwide, and delayed diagnosis is an important contributor to poor clinical outcomes. Earlier and more accurate diagnosis of small peripheral pulmonary nodules may facilitate timely clinical decision-making and treatment.
The Ion Endoluminal System is a robotic-assisted bronchoscopy platform designed to provide access to peripheral pulmonary lesions. When integrated with mobile cone-beam computed tomography (mCBCT), the system may provide additional imaging information to support localization of small pulmonary nodules during bronchoscopic biopsy. However, prospective clinical data on the diagnostic performance of this integrated approach in small, bronchus sign-negative pulmonary nodules remain limited.
ROBISN is a prospective, multicenter, observational study designed to evaluate the clinical performance of bronchoscopic biopsy using the integrated Ion Endoluminal System and mCBCT platform in patients with small peripheral pulmonary nodules that are considered challenging for conventional bronchoscopic biopsy.
The study will enroll adult patients who are already clinically planned to undergo bronchoscopic biopsy using the Ion Endoluminal System and mCBCT as part of their routine clinical care. Eligible patients will have a single target pulmonary nodule with a maximum diameter of 20 mm or less, measured on axial, sagittal, and coronal computed tomography images. The target nodule must also be bronchus sign-negative on thin-section computed tomography.
This is an observational study, and participation in the study will not determine the patient's clinical diagnostic or treatment pathway. All bronchoscopic procedures, imaging, biopsy techniques, pathology assessments, subsequent diagnostic evaluations, and treatment decisions will be performed according to the participating institution's standard clinical practice and the treating physician's judgment.
The study will prospectively collect information related to patient and target lesion characteristics, procedural details, use of adjunctive imaging and biopsy modalities, biopsy results, pathology findings, procedure-related adverse events, and subsequent clinical information used to establish the final diagnosis of the target pulmonary nodule.
Diagnostic outcomes will be assessed using information obtained from the index bronchoscopic biopsy together with subsequent pathology, imaging, clinical follow-up, or other diagnostic procedures, as applicable. Follow-up information will be collected prospectively to evaluate the diagnostic outcome of cases in which the initial biopsy result is not immediately definitive and to characterize the clinical course of the target lesion over time.
Safety outcomes will include clinically relevant procedure-related adverse events, including events such as pneumothorax and bleeding. Other procedural and clinical variables will also be collected to characterize the performance of the integrated Ion Endoluminal System and mCBCT approach in this patient population.
The results of this study are intended to provide prospective, multicenter evidence regarding the use of robotic-assisted bronchoscopy combined with mCBCT for the biopsy of small, bronchus sign-negative pulmonary nodules and to better characterize its diagnostic performance and safety in routine clinical practice.
Adults planned to undergo a pulmonary nodule biopsy using the Ion Endoluminal System and integrated mobile cone beam CT (mCBCT)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with a single small, bronchus sign-negative pulmonary nodule who are clinically planned to undergo bronchoscopic biopsy using the integrated Ion Endoluminal System and mobile cone-beam computed tomography (mCBCT) platform as part of routine clinical care.
Diagnostic yield assessed using the ATS/ACCP consensus definition.
Diagnostic yield will be calculated according to the ATS/ACCP consensus definition using the diagnosis established from the index biopsy procedure.
Time frame: At completion of index biopsy procedure
Intermediate diagnostic yield
Time frame: Through establishment of final diagnosis (up to 12 months)
Sensitivity for malignancy
Time frame: Through establishment of final diagnosis (up to 12 months)
Rate of pneumothorax (with and without intervention or hospitalization)
Time frame: within 7 days post procedure.
Rate of intra-procedure airway bleeding graded using the Nashville Bleeding Scale
Time frame: Procedure day
Procedure time (ssRAB catheter in or out)
Time frame: During the index biopsy procedure.
Total radiation dose
Time frame: During the index biopsy procedure.
Number of cone beam CT (CBCT) spins
Time frame: During the index biopsy procedure
Rate of successful tool in lesion (TIL)
Time frame: During the index biopsy procedure.
rEBUS view at time of tissue sampling (when radial EBUS is used)
Time frame: During the index biopsy procedure.
Rate of procedure related adverse events.
Time frame: 30 days post-procedure or until the next invasive diagnostic or therapeutic intervention, whichever occurs first.
Time from identification of nodule to diagnosis
Time frame: Through establishment of final diagnosis (up to 12 months).
Rate and type of imaging and/or diagnostic interventions performed from nodule identification to procedure
Time frame: Up to the index biopsy procedure.
Percentage of patients and timepoint for invasive mediastinal staging.
Time frame: Through establishment of final diagnosis (up to 12 months).
Adequacy of biopsy sample for molecular/immunohistochemistry (IHC) testing when indicated.
Time frame: Up to 30 days after the index biopsy procedure.
Patient-reported outcomes measured with the EQ-5D-5L.
Time frame: Up to 7 days post-procedure.
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Nov 2028, 22 months later.
Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 22 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.